Agilon Health, Inc. (AGL) Company Overview

agilon health, inc. (NYSE: AGL) partners with independent primary-care groups serving older adults. It supplies capital, data, payor contracting, and operating infrastructure so local physicians can manage Medicare populations under value-based arrangements while retaining practice independence. That purpose is summarized on the official Our Story page.

How does the Total Care Model work in plain English?

The operating core is global capitation. Health plans pay a monthly amount for each attributed Medicare Advantage member. Local risk-bearing entities use that revenue to cover claims, physician compensation, and care-management costs. Any surplus after those costs can support agilon’s platform and shared partner economics; an unfavorable cost outcome creates downside risk.

Why does agilon matter in value-based care?

Community-based groups often have trusted patient relationships but lack the actuarial tools, capital, data integration, and multi-payor contracting scale needed to accept population risk. agilon attempts to provide those capabilities without buying the practice. The strategic question is whether independent groups can achieve payer-scale economics while preserving local clinical control.

Where does revenue actually come from?

Substantially all consolidated revenue comes from Medicare Advantage payors, not software subscriptions or visit fees. Contracts generally run for one to three years, so rates, risk adjustment, benefit design, and medical-cost assumptions can reset quickly. The 2025 Form 10-K shows why revenue alone is incomplete: billions of capitated revenue can still produce losses when claims outpace premiums.

Why is medical margin more important than headline revenue?

Medical margin equals medical services revenue minus medical services expense. In FY2025, expense reached $5.978B against $5.921B of medical services revenue. That mismatch explains the weak year more directly than the modest revenue decline. In this model, a small change in the medical-cost ratio can outweigh membership growth.

Why is Medicare Advantage the consolidated revenue engine?

Medicare Advantage membership drives consolidated capitation revenue and claims. At March 31, 2026, MA membership was 426,300, down 13%, while revenue declined 7%. Premium rates and member mix therefore partly offset lower volume. Researchers should separate scale from unit economics: a smaller membership base can be more valuable if medical margin per member improves.

How should students interpret agilon’s KPIs?

Why did better unit economics outweigh lower membership?

Q1 2026 improved operating quality without restoring growth. Medical services expense fell to about 89% of revenue from 91%, general and administrative expense declined 18%, and management reserved for a 7.4% MA cost trend. These changes lifted profit measures despite lower membership. The Q1 2026 earnings release supports a turnaround interpretation, but only for one quarter.

Why does reported net income need context?

Q1 2026 operating income was about $4.0M. Net income also included $11.7M of equity-method income, $16.0M of other income, and a $19.0M discontinued-operations adjustment. Medical margin, platform cost, cash flow, and recurring ACO contribution are therefore better run-rate indicators. The Q1 2026 Form 10-Q provides the reconciliation.

The July 2026 official ACO REACH update provides evidence beyond accounting profit. Eight ACOs served about 121,000 beneficiaries, returned $54M to the Medicare Trust Fund, and achieved a 96% average quality score. Four earned perfect quality scores and five qualified for the High Performers Pool.

Why is ACO performance strategically valuable but financially different?

Since 2021, agilon-affiliated ACOs have generated $510M of gross savings and $125M of Medicare Trust Fund savings. This strengthens credibility with physicians, CMS, and payors. Financially, the unconsolidated entities appear through equity-method income rather than segment revenue; in Q1 2026 they contributed about $27M of Adjusted EBITDA.

ACO REACH ends after 2026, and the successor LEAD model begins in 2027. Until its economics and agilon’s participation are clear, current ACO results are strong proof of capability but should not be extrapolated unchanged into a terminal forecast.

Why was scale built before durable economics were proven?

agilon expanded its physician platform before proving durable risk economics. The 2024-2025 cost environment then showed that scale cannot offset weak reserves, utilization pressure, or mispriced contracts.

1. 2016
   Company founded. The original strategic choice was to partner with independent physician groups rather than build a fully employed clinic chain.
2. 2017
   First anchor partnership launched. This established the long-duration, local-group model that still defines customer acquisition and switching costs.
3. 2021
   Public listing and ACO participation. Public capital supported expansion, while the ACO model broadened the platform beyond Medicare Advantage.
4. 2023
   Hawaii operations sold. The transaction became discontinued operations and later produced a contingent adjustment, illustrating the complexity of market exits.
5. 2024-2025
   Medical-cost pressure overwhelmed scale. FY2025 revenue remained $5.933B, but the company recorded a $160.0M gross loss and a $391.3M net loss.
6. Mar-May 2026
   Capital-market repair. A 1-for-25 reverse split took effect March 30, and NYSE minimum-price compliance was regained in May.
7. May 2026
   Tim O’Rourke became CEO. The leadership change moved a former Humana and Centene executive into the turnaround role while co-founder Ron Williams remained chairman.

The reverse split was a listing-compliance action, not an operating improvement. The official announcement makes the adjustment explicit, so historical prices and share counts require split adjustment. The more important question is whether the smaller 2026 footprint can produce repeatable medical margin.

Why can long-term physician partnerships create switching costs?

The core resource is the embedded relationship with community physician groups. A risk-bearing launch requires payor contracts, claims data, reserves, compensation design, and local operating leadership. Once integrated, switching can be disruptive. The advantage is relational and operational—not patent-protected—so it depends on partner satisfaction and credible economics.

Why is multi-payor capability both a moat and a source of complexity?

Physician groups want consistent care management across several health plans. agilon’s multi-payor approach can be more attractive than a captive single-payer model, but each contract adds rate, benefit, risk-adjustment, and settlement complexity. The IPO filing named ChenMed, Oak Street Health, Optum, VillageMD, local networks, hospitals, and health systems as competitive references; the official S-1 emphasized physician relationships, outcomes, payor ties, local leadership, and economics.

Why is liquidity stronger than the recent earnings history?

agilon ended Q1 2026 with substantially more cash and securities than debt, reducing near-term refinancing risk. Yet its balance sheet is claims-heavy: medical claims payable exceeded $1.0B, and risk-bearing agreements generally require capital equal to about 1%-3% of projected gross revenue. Cash can move sharply with claim timing, settlements, and reserves.

What must improve for cash generation to become durable?

FY2025 remains the weak baseline: operating cash use was $105.8M and the Adjusted EBITDA loss was $296.2M. Durable cash generation requires positive medical margin across seasonal claims, lower platform cost per member, and contracts that price risk adequately. Liquidity buys time; it does not replace underwriting discipline.

AGL has one share class and one vote per share. The 2026 proxy used 16,605,995 split-adjusted shares outstanding at March 31, 2026. Because its Schedule 13G data have different underlying dates, the table is a governance map rather than a live trading register.

Why does CD&R remain the anchor shareholder?

CD&R’s stake is influential but below majority control, so major actions still require broader board and shareholder support. Unlike a founder-controlled dual-class company, AGL’s voting influence is concentrated but proportional to economic ownership.

How are the new CEO’s incentives structured?

Tim O’Rourke became CEO on May 7, 2026, while co-founder Ron Williams remained chairman. The appointment Form 8-K disclosed an $850,000 salary, a 100% target bonus, 120,000 RSUs, and 200,000 performance units. The package is equity-sensitive, but medical margin, cash flow, partner retention, and contract economics remain the better execution measures.

Where is the most credible growth opportunity?

The credible opportunity is profitable growth, not maximum membership. agilon can deepen existing partnerships, improve coding and care coordination, negotiate better-aligned payor terms, and use its ACO record to recruit physicians. A stable member base could also lower platform support cost per member.

Which risks are most material to the financial model?

The main downside is adverse medical-cost development. Revenue is prospective, while final claims emerge later, making reserve adequacy and utilization forecasting central. Mispriced contracts or weak risk-score capture can turn growth into losses; partner exits can then shrink scale and strand platform costs.

The next checkpoint is the second-quarter report scheduled for August 5, 2026, according to the official announcement. Medical margin, reserve commentary, cash flow, and guidance matter more than membership alone.

agilon is a clear case study in the difference between revenue scale and economic quality. Delegated risk produces a large top line, but that revenue has limited value unless claims are controlled, contracts are priced correctly, partners remain aligned, and recurring medical margin covers the platform. The strongest evidence is the physician model and ACO savings record; the weakest is the recent profitability and cash-flow history.

For a DCF, the pivotal question is whether Q1 2026 began a repeatable improvement in medical margin and free cash flow. A sound model should separate MA operations from ACO contribution, normalize non-operating items, forecast medical-cost ratio and platform support cost explicitly, and use wide terminal-margin sensitivities.